tbuckley/cabot-search huggingface dataset:
AB0611 PREDICTORS OF RA DEVELOPMENT IN PATIENTS WITH ACPA POSITIVE UNDIFFERENTIATED ARTHRITIS: A 2 TO 20 YEARS FOLLOW-UP STUDY OF THE ARTHRITIS UCLOUVAIN BRUSSELS COHORT
Authors: P. Durez, S. Dierckx, F. Natalucci, C. Triaille, E. Sapart, C. Van Mullem, S. De Montjoye, L. Meric de Bellefon, M. Doyen, T. Sokolova, A. Avramovska
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Patients with Undifferentiated Arthritis (UA), positive for Anti-citrullinated protein antibodies (ACPA) are at high risk of progressing to Rheumatoid Arthritis (RA). However, some of them may experience spontaneous remission. To prevent overtreatment and potential side effects, the identification of predictors of RA development is crucial. <h3>Objectives:</h3> This research aims to analyze the evolution of UA patients with ACPA evolving RA or not after 2 to 20 years of follow-up and to determine the predictive factors. <h3>Methods:</h3> A prospective analysis of an early arthritis cohort of 700 patients from 2003 to 2021 was analyzed. Among them, UA was defined if they did not fulfill the 1987 ACR and the ACR/EULAR 2010 criteria. Patients with baseline erosion or joint space narrowing were excluded from the study. A detailed baseline assessment was performed including all clinical characteristics and the ACR/EULAR score set components. ACPA UA patients were divided into two groups based on the progression to RA (according to the physician's diagnosis) and the initiation of Methotrexate. All csDMARDs were prohibited during the follow-up of UA. Differences in continuous variables between the two groups were analyzed by T-test or Mann-Whitney test depending on normality. Levene's test was used to analyze the equality of variance. Chi-squared or Fisher's exact test was applied to analyse the significance of the association between categorical variables. Spearman's correlation test was used to assess the presence of significant correlations between variables. <h3>Results:</h3> A total cohort of 96 ACPA UA patients was analyzed. 35 patients (36.4%) were still defined as UA during the last follow-up visit and 61 (63.6%) developed RA after a mean follow-up of 2 years ± 2.09. Baseline characteristics between both groups are compared in Table 1. At baseline, ACPA UA patients who developed RA had significantly more small-TJC (0.43 ± 0.9 versus 1.3 ±2.0; p=0.004), small-SJC (0.1 ± 0.2 versus 0.5 ± 0.9; p=0.001) and ACR/EULAR 2010 score (4.3 ± 0.8 versus 5.1 ± 1.3; p&lt; 0.001). <b>Table 1.</b> Baseline comparison of UA and RA Cohort. <h3>Conclusion:</h3> We confirm that ACPA UA patients are at high risk of developing RA. Baseline evaluation of the ACR/EULAR 2010 including the number of tender and swollen of small joints score is a predictor for RA. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS1167 ASSOCIATIONS BETWEEN CRITERIA ITEMS IN SLE PATIENTS IN THE EULAR/ACR CLASSIFICATION CRITERIA COHORT
Authors: M. Aringer, K. Costenbader, M. Mosca, T. Dörner, S. R. Johnson
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> During the development of the EULAR/ACR classification criteria for systemic lupus erythematosus (SLE), associations between items were analyzed in the early SLE cohort and the Eurolupus cohort [1]. Meaningful associations were found between items within organ systems, but not between organ systems, leading to the domains of the criteria. <h3>Objectives:</h3> To revisit the question of associations within the EULAR/ACR classification criteria cohort. <h3>Methods:</h3> Complete data on the presence or absence of every one of the 23 single EULAR/ACR classification criteria items were analyzed for all of the 1,197 SLE patients of the EULAR/ACR cohort [2], independent of their reaching or not reaching classification. Associations between individual items were analyzed in an unbiased approach. In this 23x23 table, associations were accordingly tested for 529 pairs, and, by Bonferroni's correction, significance was defined as a p-value &lt;9.45e<sup>-5</sup>. <h3>Results:</h3> After correcting for the 529 comparisons, 29 correlations remained significant (Table 1). With the exception of C3 AND C4 low and C3 OR C4 low, which are, by definition, mutually exclusive, correlations within the domains were always stronger. Associations between items of different domains were weak, with correlation coefficients of 0.12 to 0.25. We found correlations between proteinuria and both antibodies to double-stranded DNA (dsDNA) and low complements, apparently driven by proliferative lupus nephritis (Table 1). Proteinuria was associated with hemolytic anemia. Low complements were associated with antibodies to dsDNA and Sm and with autoimmune cytopenias. Pleural or pericardial effusion was associated with fever (r= 0.12) and non-scarring alopecia with anti-Sm antibodies (r=0.13). Joint involvement was negatively correlated with lupus nephritis (r=-0.13 to -0.16) and thrombocytopenia (r=-0.14). <h3>Conclusion:</h3> These results underline the relevance of the EULAR/ACR SLE criteria domain structure. The association between anti-Sm and non-scarring alopecia, the association of serositis and fever, and the negative association between joint involvement and both nephritis and thrombocytopenia are of interest and warrant further investigation. <h3>REFERENCES:</h3> [1] Touma et al, <b>Arthritis Care Res (Hoboken</b>) 2020; 72: 1820-1826. [2] Aringer et al, <b>Ann Rheum Dis</b> 2019; 78: 1151-1159. <h3>Acknowledgements:</h3> The SLE classification criteria project was jointly supported by EULAR and the ACR. <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0604 SPLENIC METABOLIC UPTAKE IN FDG-PET/CT ASSOCIATED WITH RISK OF FUTURE CARDIOVASCULAR THROMBOSIS EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS
Authors: C. M. Hong, S. J. Lee
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> <b>Objectives:</b> This study assessed whether splenic and arterial activity measured by positron emission tomography/ computed tomography (PET/CT) predict the risk of thrombosis events beyond conventional risk factors in patients with rheumatoid arthritis (RA). <h3>Methods:</h3> We enrolled 102 patients with active RA who underwent fluorine-18-fluorodeoxyglucose (FDG) PET/CT and disease activity evaluation at the same time. Cardiovascular thrombosis (CVT) events included stroke, acute coronary syndrome, heart failure or death and deep vein thrombosis (DVT). Thrombosis events were independently evaluated, while blinded to activity of PET/CT, during follow up periods. FDG uptake by nuclear medicine physician was examined in the spleen and ascending aorta and blood pool activity of superior vena cava as SUV (standardized uptake values) and target-to-background-ratio (TBR) while blinded to CVT events. <h3>Results:</h3> Mean follow-up duration was 62.64 ± 33.56 months and 21 patients developed CVT events. Both splenic and arterial TBR were significantly increased in patients with subsequent CVT events compared to in patients without (2.15 ± 0.60 vs 1.83 ± 0.34, p = 0.002, 1.72 ± 0.21 vs 1.58 ± 0.22, p = 0.015). The correlation between splenic and arterial TBR was significant using Pearson's test (r = 0.60, p &lt; 0.001). Splenic TBR was associated with an increased risk of CVT events after adjustment for conventional CVD risk factors [hazard ratio (HR): 2.47; 95% confidence interval (CI): 1.02 to 5.99; p = 0.046]. Moreover, association between splenic TBR and CVT events increased significant after adjustment for disease activity (HR: 4.44; CI: 1.23 to 15.98; p = 0.023). <h3>Conclusion:</h3> Our results show splenic metabolic uptake in FDG-PET/CT in patients with RA provide information for subsequent CVT events beyond conventional risk factors. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB0538 WARRICK SCORE IN ASSESSING PULMONARY INVOLVEMENT IN RHEUMATOID ARTHRITIS PATIENTS: RELIABILITY AS A PROGRESSION PREDICTOR AND ASSOCIATIVE FINDINGS
Authors: D. Temiz Karadağ, S. Doğan, N. Gokcen, O. Sadioglu Cagdas, A. Yazici, A. Cefle
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Interstitial lung disease (ILD) stands as a prominent cause of mortality among rheumatoid arthritis (RA) patients, significantly impacting overall outcomes. <h3>Objectives:</h3> This study aimed to explore the utility of the Warrick score in detecting the extent and severity of pulmonary involvement in RA-ILD, along with its association with factors influencing progression and its diagnostic capacity for predicting progression. <h3>Methods:</h3> A total of 77 consecutive RA-ILD patients were enrolled. Warrick scores (WS), including total, severity, and extent scores, were computed based on baseline high-resolution computed tomography (HRCT) used for diagnosis and consecutive HRCT scans used for follow-up. Radiographic progression was defined as an increase in lung areas affected by abnormalities or the emergence of at least one new abnormality. Relationships between WS and pulmonary function tests (%FVC, %DLCO), demographic characteristics, disease activity score (DAS28-ESR), and laboratory data were analyzed. <h3>Results:</h3> The study comprised 77 patients (45 women/32 men) with a mean age of 60.6±8.7 years and a mean disease duration of 8.4±7.1 years. The time interval between consecutive HRCT scans was 5.4±3.5 years. Positive correlations were observed between severity score and age at RA diagnosis, age at ILD diagnosis, and DAS28-ESR (r=0.359, p=0.001; r=0.372, p=&lt;0.001; r=0.298, p=0.014, respectively); extent score and age at RA diagnosis, age at ILD diagnosis, and DAS28-ESR (r=0.364, p=0.001; r=0.318, p=0.005; r=0.255, p=0.038, respectively); total score and age at RA diagnosis, age at ILD diagnosis, and DAS28-ESR (r=0.376, p=&lt;0.001; r=0.367, p=0.001; r=0.280, p=0.022, respectively). Warrick-severity, extent, and total scores significantly increased after a median time of 5 years (6.48±3.75 vs. 5.26±2.86, p&lt;0.001; 5.94±3.21 vs. 5.08±2.75, p=0.001; 12.42±6.68 vs. 10.34±5.39, p&lt;0.001, respectively). ROC curve analysis demonstrated AUCs of 0.946, 0.954, and 0.976 for the annual change rates of total, severity, and extent Warrick scores, respectively (p&lt;0.001 for all). A Warrick-severity score change rate of 0.028, extent score change rate of 0.022, and Warrick-total score change rate of 0.069 exhibited sensitivities of 91%, 94%, and 97%, respectively, and specificities of 98% for all. Multivariable logistic regression indicated that individuals over 50 years old had a fourfold increased risk of progression. <h3>Conclusion:</h3> The Warrick score proves to be an objective method for assessing the extent and severity of radiological involvement, demonstrating associations with other parameters and serving as a reliable tool for evaluating disease progression. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0816 HRCT ANNUAL SCORE: IT MAY BE USEFUL TO MONITOR HRCT ANNUAL SCORE TO TRACK PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS
Authors: S. Kalender, T. Demirci Yildirim, F. Dulger, S. Gulle, M. Birlik
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) frequently affects the lung and interstitial lung disease (ILD) is a common manifestation and leading cause of mortality. <h3>Objectives:</h3> The study aimed to investigate the predictive power of annual change of HRCT score and annual change of forced vital capacity (FVC) on mortality. <h3>Methods:</h3> Patients with SSc associated ILD (SSc-ILD) who had HRCT at least twice with a one-year interval were included in the study. HRCT scoring system was used for assessment of SSc-ILD (Table 1). The annual change of HRCT score was calculated as last HRCT score minus initial HRCT score divided by the time (years) between last and initial HRCT. We also calculated the annual change in FVC as initial FVC minus last FVC divided by the time (years) between last and initial FVC. We performed a receiver operating characteristic (ROC) analysis for predictive power of the annual change of HRCT score and FVC. The cut of value of annual change of HRCT score and FVC was determined by maximum Youden Index. <h3>Results:</h3> A total of 100 patients were included in final analysis, mean age was 50,5±11,5 years and 91 (91%) patients were female. The median follow-up duration was 113.5 months (minimum-maximum: 17.0–196.0 months) and 19 (19%) patients died during follow-up period. ROC analysis showed that the annual change of HRCT score and the annual change of FVC had good predictive power for mortality (AUC: 0.69 and 0.65 respectively). Patients with an annual increase in HRCT score of more than 0.39 had 4.4 times higher risk for mortality compared to those without (95% CI, 1.7–11.2). Patients with an annual decrease in FVC of more than 77.6 mL had 5.2 times higher risk for mortality compared to those without (95% CI, 1.7–15.9) (Table 2). Both an increase in annual HRCT score and decrease in annual FVC indicate poor prognosis. Five of seven patients (71.4%) with an increase in annual HRCT score and decrease in FVC died during the follow-up period. <h3>Conclusion:</h3> We developed a parameter called the annual HRCT score to monitor the progression of patients with SSc-ILD. An increase in annual HRCT score indicates disease progression and associated with worse survival in patients with SSc-ILD. <h3>REFERENCES:</h3> [1] Moore, O. A., Goh, N., Corte, T., Rouse, H., Hennessy, O., Thakkar, V.,... &amp; Nikpour, M. (2013). Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease. Rheumatology, 52(1), 155-160. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
AB1222 HIGH PREVALENCE OF INTERSTITIAL LUNG DISEASE IN A COHORT OF PATIENTS WITH EARLY SYSTEMIC SCLEROSIS
Authors: L. J. Cajas Santana, M. C. Torres Villarreal
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Interstitial Lung Disease (ILD) is the leading cause of mortality in patients with systemic sclerosis (SSc). It has been observed before cutaneous involvement (Early SSc,eSS) or Scleroderma sine scleroderma (ssSSc). <h3>Objectives:</h3> This study aims to establish the prevalence of ILD in eSS and ssSS patients and explore potential risk factors associated within a Colombian population. <h3>Methods:</h3> We analyzed data from a cohort of SSc patients at a university hospital in Bogotá, Colombia. Patients with cutaneous sclerosis (Rodnan &gt;0) were excluded. Patients meeting the 2013 ACR/EULAR classification criteria were categorized as "ssSSc," while those meeting the VEDOSS criteria were categorized as "eSS." Group comparisons were made, and chest tomography images and pulmonary function tests were reviewed to ascertain the presence and severity of ILD. We determined the proportion of ILD patients and evaluated potential risk factors associated with these two populations. <h3>Results:</h3> Out of a total of 353 patients, we found that 80 (22.6%) had "eSS," and 51 (14.4%) had "ssSSc." Table 1 describes the population's characteristics and differences between these groups. The proportion of patients with ILD was 32% in the eSS and 27% in the ssSSc group, with extensive involvement (&gt;20%) in 7.5% of patients. No significant relationship was found between gender, duration of Raynaud's phenomenon, digital ulcers, telangiectasias, or other clinical variables and the presence of ILD. It was observed that the type of antibody was associated with ILD, with an odds ratio (OR) for SCL-70 of 16.1 (95% CI: 1.6-160) for eSS and 16.5 (95% CI: 1.6-168) for ssSSc. Conversely, the presence of anticentromere antibodies conferred a protective effect, with an OR of 0.22 (95% CI: 0.1-0.63) and 0.18 (95% CI: 0.39-0.88), respectively. No relationship was found with ANAs in patterns other than centromere. <h3>Conclusion:</h3> ILD occurs in approximately one-third of patients, even in those at early stages of the disease or without cutaneous involvement. The primary risk factor appears to be the presence of SCL-70 antibodies, while anticentromere antibodies act as protective factors. <h3>REFERENCES:</h3> [1] Gabriele Valentini, Giovanna Cuomo, Giuseppina Abignano. Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features. Rheumatology 2011;50:317–323. <b>Table 1.</b> Describes the population's characteristics and differences between groups <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> LUIS JAVIER CAJAS SANTANA Boehringer, Pfizer, Novartis, Jannsen, Maria Carolina Torres Villarreal: None declared.
AB0921 IMPACT OF TREATMENTS ON FATIGUE IN AXIAL SPONDYLOARTHRITIS, A SYSTEMATIC REVIEW
Authors: F. Verhoeven, C. Delcourt, O. Fakih, M. Chouk, C. Prati, D. Wendling
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Axial spondyloarthritis (axSpA) is particularly associated with fatigue. Fatigue is multifactorial and several evaluation scales are available. Current treatments are effective on all or some of the symptoms of axSpA. <h3>Objectives:</h3> The aim of this systematic review of the literature is to assess the effect of treatment of axSpA on fatigue. <h3>Methods:</h3> A systematic review of all articles published before 01/09/23 on Pubmed, Cochrane, Embase, was performed by two independent reviewers following PRISMA recommandations. We included controlled interventional studies, cohorts and before-and-after studies conducted in patients with axial spondyloarthritis meeting ASAS 2009 criteria and measuring fatigue either as a primary or secondary outcome at 12 weeks and/or 52 weeks. We excluded studies involving non-recommended drug treatments, those not written in English, case reports, abstracts, systematic reviews, meta-analyses and studies with missing data. <h3>Results:</h3> A total of 1670 studies were identified. After exclusion of duplicates, 1590 were filtered and 149 selected for full reading. Finally, 34 studies were selected for analysis. Twelve studies evaluated anti-TNF, 11 highlighting a significant reduction in fatigue measured by various scores (FACIT, MFI, EVA, EN, FSS) and 1 failed to showed efficacy in non radiographic axSpA. Among the 4 studies evaluating anti IL17, 3 showed a significant reduction in fatigue, with a dose effect for Secukinumab and 1 failed to to decrease the fatigue in non radiographic axSpA. For JAK inhibitors, 2 studies showed a reduction in fatigue. With regard to non pharmacological treatments, 16 studies were selected, 11 of which showed a reduction in fatigue. The positive studies concerned physical activity (Qiquong, home exercise, high-intensity exercise, pilates, balneotherapy), cryotherapy and magnetotherapy. Negative studies involved infrared sauna, aquatic relaxation and some home or high-intensity physical activity. Two studies have shown that the addition of physical activity to anti-TNF therapy leads to greater improvement in fatigue. Finally Three studies showed a greater efficacy on fatigue in men. <h3>Conclusion:</h3> This review shows a beneficial effect of disease-modifying therapies on fatigue in axSpA in the short and medium term with slice differences according to the gender and the présence of radiographic modifications. The addition of non-pharmacological management (physical activity in the broad sense) represents a significant avenue for improvement. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>
POS0817 ULTRASONOGRAPHIC EVALUATION OF HAND AND WRIST JOINT IN PATIENTS WITH SYSTEMIC SCLEROSIS
Authors: Z. Ermancik, M. E. Yayla, A. Ilbay, N. Göveç Giynaş, S. Sezer, E. Uslu Yurteri, A. Ates, T. M. Turgay
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic sclerosis (SSc) is a systemic disease characterized by vascular damage, autoimmunity, and fibrosis. Musculoskeletal system findings are quite common in SSc. Ultrasonography (US) in patients with SSc is used to evaluate periarticular soft tissues and detect inflammatory lesions. Power Doppler Ultrasound (PDUS) allows evaluating the vascularity in the examined area and detecting signs of active inflammation. <h3>Objectives:</h3> This study aimed to reveal the US findings of the hand and wrist joints of patients with SSc and to compare the characteristics of SSc patients with and without synovitis. <h3>Methods:</h3> The current study is a cross-sectional study comparing 50 SSc patients and 50 healthy controls between February 2023 and September 2023. Metacarpophalangeal (MCP), Proximal interphalangeal (PIP), Distal interphalangeal (DIP) and wrist joints were evaluated with US for the presence of synovitis, synovial hypertrophy, tenosynovitis, erosion, osteophytes, and calcinosis. <h3>Results:</h3> Synovitis (p&lt;0.001), synovial hypertrophy (p&lt;0.001), tenosynovitis (p&lt;0.001), and calcinosis (p=0.012) were more common in SSc patients compared to healthy controls. In SSc patients, synovitis (40%) and synovial hypertrophy (32%) were most common in the wrist joint. Synovial effusion and tenosynovitis were generally mild. Comparison of USG findings of SSc and healthy controls is presented in Table 1. Patients with synovitis were older and had higher CRP and ESR (Table 2). Hydroxychloroquine was used more frequently in those with synovitis (54.2% vs 23.1%, p = 0.024), while the use rates of other treatment agents were similar. There was no difference between hand USG findings between dcSSc and lcSSc patients. <h3>Conclusion:</h3> In conclusion, synovitis, synovial hypertrophy, and tenosynovitis are more common in SSc patients than in healthy patients, however synovitis is generally mild. Patients with synovitis are older and CRP and ESR values are higher in these patients. <h3>REFERENCES:</h3> [1] Avouac J, Clements PJ, Khanna D, Furst DE, Allanore Y. Articular involvement in systemic sclerosis. Rheumatology (Oxford). 2012;51(8):1347-56. [2] Elhai M, Guerini H, Bazeli R, Avouac J, Freire V, Drape JL, et al. Ultrasonographic hand features in systemic sclerosis and correlates with clinical, biologic, and radiographic findings. Arthritis Care Res (Hoboken). 2012;64(8):1244-9. <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>